The role of thioredoxin system in cancer: strategy for cancer therapy

Purpose Cancer, a major public health problem, exhibits significant redox alteration. Thioredoxin (Trx) system, including Trx and Trx reductase (TrxR), as well as Trx-interacting protein (TXNIP) play important roles in controlling the cellular redox balance in cancer cells. In most cancers, Trx and...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Cancer chemotherapy and pharmacology Ročník 84; číslo 3; s. 453 - 470
Hlavní autori: Jia, Jin-Jing, Geng, Wen-Shuo, Wang, Zhan-Qi, Chen, Lei, Zeng, Xian-Si
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Berlin/Heidelberg Springer Berlin Heidelberg 01.09.2019
Springer Nature B.V
Predmet:
Antineoplastic Agents - therapeutic use
Antitumor activity
Cancer
Cancer Research
Cancer therapies
Cytotoxicity
Humans
Medicine
Medicine & Public Health
Molecular Targeted Therapy
Neoplasms - drug therapy
Neoplasms - metabolism
Oncology
Pharmacology/Toxicology
Public health
Reductase
Review Article
Thioredoxin
Thioredoxins - antagonists & inhibitors
Redox
Inhibitor
Thioredoxin system
Combined therapy
Cancer
ISSN:0344-5704, 1432-0843, 1432-0843
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Purpose Cancer, a major public health problem, exhibits significant redox alteration. Thioredoxin (Trx) system, including Trx and Trx reductase (TrxR), as well as Trx-interacting protein (TXNIP) play important roles in controlling the cellular redox balance in cancer cells. In most cancers, Trx and TrxR are usually overexpressed and TXNIP is underexpressed. In recent years, some agents targeting Trx, TrxR, and TXNIP were used to explore a therapy approach for cancer patients. Methods A systematic search of PMC and the PubMed Database was conducted to summarize the potential of Trx system inhibitors for cancer treatment. Results In this article, we first summarize the functions of Trx, TrxR, and TXNIP in cancers. We also review some small molecule inhibitors of Trx/TrxR and d -allose (TXNIP inducer) and discuss their antitumor mechanisms. We highlight the combined inhibition of Trx system and GSH system in cancer therapy. We expect that a highly specific and selective antitumor agent with no cytotoxicity on human normal cells could be developed in the future. Conclusion In conclusion, Trx system may be very promising for clinical therapy of cancer in the future.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Literature Review-3
ObjectType-Review-3
content type line 23
ISSN:0344-5704
1432-0843
1432-0843
DOI:10.1007/s00280-019-03869-4